Skip to content

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

NT-proBNP and Clinical Outcomes in Patients With HFrEF According to Atrial Fibrillation: Insights From QUEST.

BACKGROUND The Chinese traditional medicine qiliqiangxin (QLQX) improves outcomes in patients with heart failure with reduced ejection fraction (HFrEF) when added to guideline-directed medical therapy. OBJECTIVES This post hoc analysis of the QUEST (Qiliqiangxin in Heart Failure: Assessment of Reduction in Mortality)...

L. Shen, Jun-Ru Li, I. Cheang et al. · 0 citations
Open access Oct 2026

Effect of traditional Chinese medicine Qiliqiangxin in patients With HFrEF treated with sacubitril/valsartan: the QUEST trial

Heart failure with reduced ejection fraction (HFrEF) remains a leading cause of cardiovascular morbidity and mortality globally, despite recent advances in therapy, and new treatments that have added benefit are still needed. Qiliqiangxin (QLQX), a Traditional Chinese Medicine (TCM) formulation, has demonstrated...

I. Cheang, X. Zhu, L. Shen et al. · 0 citations
Review Open access Sep 2026

Residual Apolipoprotein B Elevation Despite PREVENT-Guided LDL-C Goal Attainment Among Adults Without Known ASCVD.

BACKGROUND Low-density lipoprotein cholesterol (LDL-C) goal attainment is central to primary atherosclerotic cardiovascular disease (ASCVD) prevention, but LDL-C may not fully reflect the burden of apolipoprotein B (ApoB)-containing atherogenic particles. The prevalence and clinical correlates of residual ApoB elevatio...

Yan-Ping Shi, Yuan Tang, Meng-Ting Wang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.